Amicus Therapeutics will acquire Scioderm for its Zorblisa (topical 6% allantoin for the treatment of epidermolysis bullosa)

Rare disease biopharmaceutical group, Amicus are to acquire Scioderm and further develop their EB wound healing cream, Zorblisa.

They must have studied the data emerging from clinical trials so it’s a positive indication for this potential treatment. Well done to Amicus for recognising that EB is a very serious disorder deserving of a major investment.

Read more about this emerging story here